RAPT Therapeutics to Participate in the SVB Securities Global Biopharma Conference
RAPT Therapeutics, a clinical-stage biopharmaceutical company focused on immunology, will have CEO Brian Wong participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023, at 1:40 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
RAPT Therapeutics, a clinical-stage biopharmaceutical company focused on immunology, will have CEO Brian Wong participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023, at 1:40 p.m. ET. The event will discuss RAPT's efforts in developing oral small molecule therapies for inflammatory diseases and oncology, including their drug candidates RPT193 and FLX475, aimed at targeting C-C motif chemokine receptor 4 (CCR4). Investors and interested parties can access the live webcast and archived recording on RAPT's website.
Details
News Market Reaction – RAPT
The recorded move for RAPT in the trading session of this news was +4.04%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 1:40 p.m. Eastern Time.
To access the live webcast or subsequent archived recording of the discussion, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.
About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, RPT193 and FLX475, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of inflammation and cancer, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development.
RAPT Media Contact:
Aljanae Reynolds
areynolds@wheelhouselsa.com
RAPT Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.